(Q44121213)

English

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study

scientific article published in January 1991

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

based on heuristic

inferred from title

breast carcinoma

1 reference

based on heuristic

inferred from title

author name string

J Carmo-Pereira

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

F O Costa

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

D W Miles

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

E Henriques

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M A Richards

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

R D Rubens

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

394-396

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Average relative dose intensity and the impact on design of clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New agents and new medical treatments for advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of response to therapy in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1999000

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00688864

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44121213&oldid=2206447829"